# Multiple Sclerosis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/multiple-sclerosis

> 10 upcoming FDA catalysts in multiple Sclerosis: Aubagio (teriflunomide, SNY) on May to Aug 2027 (topline data readout); Aubagio (teriflunomide, SNY) on May 2027 (primary completion); frexalimab (SNY) on Jul to Oct 2027 (topline data readout); BRIUMVI® (ublituximab, TGTX) on Jul to Oct 2027 (topline data readout); and 6 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 15, 2025 | [Zeposia (ozanimod hydrochloride) primary completion](https://sec-api.dev/pdufa/ozanimod) | BMY | Multiple Sclerosis | withdrawn | "NCT04140305 (Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04140305)) |
| October 18, 2025 | [LY3541860 primary completion](https://sec-api.dev/pdufa/ly3541860) | LLY | Multiple Sclerosis | withdrawn | "NCT06220669 (A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-18 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-11-12." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06220669)) |
| November 4, 2025 | [Kesimpta (ofatumumab) primary completion](https://sec-api.dev/pdufa/ofatumumab) | NVS | Multiple Sclerosis | completed | "NCT04788615 (Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-04 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04788615)) |
| November 2026 | [Imu-838 tablets primary completion](https://sec-api.dev/pdufa/imu-838) | IMUX | Multiple Sclerosis | scheduled | "NCT05134441 (Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Immunic AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05134441)) |
| May to Aug 2027 | [Aubagio (teriflunomide) topline data readout](https://sec-api.dev/pdufa/teriflunomide) | SNY | Multiple Sclerosis | scheduled | "NCT06141473 (Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-06 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06141473)) |
| May 2027 | [Aubagio (teriflunomide) primary completion](https://sec-api.dev/pdufa/teriflunomide) | SNY | Multiple Sclerosis | scheduled | "NCT06141473 (Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-06 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06141473)) |
| Jul to Oct 2027 | [Frexalimab topline data readout](https://sec-api.dev/pdufa/frexalimab) | SNY | Multiple Sclerosis | scheduled | "NCT07325292 (Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-15 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07325292)) |
| Jul to Oct 2027 | [BRIUMVI® (ublituximab) topline data readout](https://sec-api.dev/pdufa/ublituximab) | TGTX | Multiple Sclerosis | scheduled | "NCT07503873 (A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-31 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07503873)) |
| July 2027 | [Frexalimab primary completion](https://sec-api.dev/pdufa/frexalimab) | SNY | Multiple Sclerosis | scheduled | "NCT07325292 (Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-15 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07325292)) |
| July 2027 | [BRIUMVI® (ublituximab) primary completion](https://sec-api.dev/pdufa/ublituximab) | TGTX | Multiple Sclerosis | scheduled | "NCT07503873 (A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-31 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07503873)) |
| Mar to Jun 2028 | [Frexalimab topline data readout](https://sec-api.dev/pdufa/frexalimab) | SNY | Multiple Sclerosis | scheduled | "NCT06141486 (Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06141486)) |
| March 2028 | [Frexalimab primary completion](https://sec-api.dev/pdufa/frexalimab) | SNY | Multiple Sclerosis | scheduled | "NCT06141486 (Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06141486)) |
| Jan to Apr 2029 | [MRNA-1195 topline data readout](https://sec-api.dev/pdufa/mrna-1195) | MRNA | Multiple Sclerosis | scheduled | "NCT06735248 (A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-08 (ESTIMATED); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06735248)) |
| January 2029 | [MRNA-1195 primary completion](https://sec-api.dev/pdufa/mrna-1195) | MRNA | Multiple Sclerosis | scheduled | "NCT06735248 (A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-08 (ESTIMATED); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06735248)) |

## Drugs

- [Zeposia (ozanimod hydrochloride)](https://sec-api.dev/pdufa/ozanimod) (BMY)
- [LY3541860](https://sec-api.dev/pdufa/ly3541860) (LLY)
- [Kesimpta (ofatumumab)](https://sec-api.dev/pdufa/ofatumumab) (NVS)
- [Imu-838 tablets](https://sec-api.dev/pdufa/imu-838) (IMUX)
- [Aubagio (teriflunomide)](https://sec-api.dev/pdufa/teriflunomide) (SNY)
- [Frexalimab](https://sec-api.dev/pdufa/frexalimab) (SNY)
- [BRIUMVI® (ublituximab)](https://sec-api.dev/pdufa/ublituximab) (TGTX)
- [MRNA-1195](https://sec-api.dev/pdufa/mrna-1195) (MRNA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/multiple-sclerosis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Multiple Sclerosis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/multiple-sclerosis

```bibtex
@misc{secapidev_indications_multiple_sclerosis_20261116,
  title        = {Multiple Sclerosis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/multiple-sclerosis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_multiple_sclerosis_20261116","title":"Multiple Sclerosis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/multiple-sclerosis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
